The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
Vascular cognitive impairment no dementia (VCIND) is very common among the aged and tends to
progress to dementia, but there have been no proper large-scale intervention trials dedicated
to it. VCIND caused by subcortical ischemic small vessel disease (hereinafter, subcortical
VCIND) represents a relatively homogeneous disease process and is a suitable target for
therapeutic trials investigating VCIND. Preclinical trials showed that Butylphthalide Soft
Capsules is effective for cognitive impairment of vascular origin. In this randomized,
double-blind, placebo-controlled trial, the investigators apply fMRI study the effects of
Butylphthalide Soft Capsules in patients with VCIND.